Novo Nordisk to Establish Diabetes R&D Center in Seattle

Novo Nordisk has announced plans to establish a new centre to conduct type 1 diabetes research in the U.S.

Denmark-based Novo Nordisk has announced that the company will establish a type 1 diabetes R&D center in Seattle, U.S.

Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk, said,"With the new type 1 diabetes R&D center, we hope to accelerate the process of finding new, innovative ways of treating people with this disease. Our vision is to prevent, treat and ultimately cure diabetes."

The unique concept behind the new center is to pursue a translational research approach characterized by combining basic research and early proof-of-concept trials under one umbrella. This will give the new center the necessary scientific foundation to move early-stage discovery projects rapidly from animal models into small clinica